Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Liabilities and Shareholders Equity (2020 - 2025)

Mainz Biomed's Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $13.2 million for Q4 2024.

  • For Q4 2024, Liabilities and Shareholders Equity fell 14.09% year-over-year to $13.2 million; the TTM value through Dec 2024 reached $58.9 million, up 27.1%, while the annual FY2024 figure was $13.2 million, 14.09% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2024 was $13.2 million at Mainz Biomed, down from $15.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $20.2 million in Q4 2022 and bottomed at $673270.0 in Q4 2020.
  • The 5-year median for Liabilities and Shareholders Equity is $13.2 million (2024), against an average of $11.9 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 1391.35% in 2021 before it fell 23.87% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $673270.0 in 2020, then surged by 1391.35% to $10.0 million in 2021, then soared by 101.59% to $20.2 million in 2022, then fell by 23.87% to $15.4 million in 2023, then fell by 14.09% to $13.2 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Liabilities and Shareholders Equity are $13.2 million (Q4 2024), $15.4 million (Q4 2023), and $20.2 million (Q4 2022).